Free shipping on all orders over $ 500

Ozuriftamab vedotin

Cat. No. M59066

All AbMole products are for research use only, cannot be used for human consumption.

Ozuriftamab vedotin Structure
Synonym:

BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC

Size Price Availability Quantity
100ug USD 295  USD295 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Ozuriftamab vedotin (BA3021) is an antibody-drug conjugate (ADC), it is composed of receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab and VcMMAE.

Immobilized ROR2 at 2 μg/mL (30 uL/well) can bind ozuriftamab vedotin, the EC50 is 0.160 ug/mL.

Human ROR2 CHO-S Cell Line were stained with ozuriftamab vedotin and negative control protein respectively, washed and then followed by PE and analyzed with FACS, the EC50 is 0.2650 μg/mL.

The drug-to-antibody ratio (DAR) of the ozuriftamab vedotin is 3.9.

Chemical Information
CAS Number 2460400-11-5
Storage Store at ≤ -20℃ for 24 months. Avoid repeated freeze-thaw cycles.
Related Antibody-Drug Conjugates (ADCs) Products
Oregovomab-MMAE

Oregovomab-MMAE is an antibody-drug conjugate (ADC).

Patritumab-MMAE

Patritumab-MMAE is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to MMAE.

Depatuxizumab mafodotin

Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) which specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can induce cell death in glioma cell lines overexpressing EGFR or EGFRvIII.

Glembatumumab vedotin

Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate (ADC) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects.

Denintuzumab-MMAF

Denintuzumab-MMAF is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells.

  Catalog
Abmole Inhibitor Catalog




Keywords: Ozuriftamab vedotin, BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC supplier, Antibody-Drug Conjugates (ADCs), inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.